

Original article

Heart Failure Survival Score in Patients With Chagas Disease: Correlation With Functional Variables

Luiz E. Ritt,^{a,b} Antonio Carlos Carvalho,^{a,c} Gilson S. Feitosa,^b Joel A. Pinho-Filho,^b Cristiano R.B. Macedo,^b Fabio Vilas-Boas,^b Marcus V.S. Andrade,^b Gilson S. Feitosa-Filho,^b Augusto J.G. Almeida,^b Marcos Barojas,^b and Renato D. Lopes^{a,c,d,*}

^aDepartamento de Cardiologia, Universidade Federal de São Paulo, Sao Paulo, Brazil

^bDepartamento de Cardiologia, Hospital Santa Izabel, Salvador, Brazil

^cThe Brazilian Clinical Research Institute, São Paulo, Brazil

^dThe Duke Clinical Research Institute, Durham, North Carolina, United States

Article history:

Received 20 October 2011

Accepted 22 December 2011

Available online 16 April 2012

Keywords:

Cardiomyopathy

Heart failure

Prognosis

ABSTRACT

Introduction and objectives: Chagas disease is a prevalent cause of heart failure in Latin America, and its prognosis is worse than other etiologies. The Heart Failure Survival Score has been used to assess prognosis in patients with heart failure; however, this score has not yet been studied in patients with Chagas cardiopathy.

Methods: The Heart Failure Survival Score was calculated in 55 patients with severe left ventricular systolic dysfunction due to Chagas disease. Correlations were assessed between the Heart Failure Survival Score and variables obtained from echocardiograms, cardiopulmonary exercise tests, quality-of-life measures, and 6-minute walking tests.

Results: Patients were distributed among New York Heart Association classes II–IV; 89% were taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 62% were taking beta-blockers, 86% were taking diuretics, and 74% were taking aldosterone receptor blockers. The mean Heart Failure Survival Score was 8.75 (0.80). The score correlated well with cardiopulmonary test variables such as peak oxygen uptake (0.662; $P < .01$), oxygen uptake at the anaerobic threshold (0.644; $P < .01$), ventilation carbon dioxide efficiency slope (–0.417; $P < .01$), oxygen pulse (0.375; $P < .01$), oxygen uptake efficiency slope (0.626; $P < .01$), 6-minute walking test (0.370; $P < .01$), left ventricle ejection fraction (0.650; $P = .01$), and left atrium diameter (–0.377; $P < .01$). There was also a borderline significant correlation between the Heart Failure Survival Score and quality of life (–0.283; $P < .05$).

Conclusions: In heart failure patients with Chagas disease, the Heart Failure Survival Score correlated well with the main prognostic functional test variables.

© 2011 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.

Puntuación Heart Failure Survival Score en pacientes con enfermedad de Chagas: correlación con variables funcionales

RESUMEN

Introducción y objetivos: La enfermedad de Chagas es una causa frecuente de insuficiencia cardiaca en América Latina, y su pronóstico es peor que el de otras etiologías. La puntuación de supervivencia en la insuficiencia cardiaca (*Heart Failure Survival Score*) se ha utilizado para evaluar el pronóstico de los pacientes con insuficiencia cardiaca; sin embargo, dicha puntuación no se ha evaluado todavía en pacientes con cardiopatía chagásica.

Métodos: Se calculó la puntuación *Heart Failure Survival Score* en 55 pacientes con disfunción sistólica ventricular izquierda grave debida a enfermedad de Chagas. Se evaluaron las correlaciones entre la *Heart Failure Survival Score* y las variables derivadas de las ecocardiografías, las pruebas de esfuerzo cardiorrespiratorias, las medidas de la calidad de vida y las pruebas de distancia recorrida en 6 min.

Resultados: Se distribuyó a los pacientes según las clases II–IV de la *New York Heart Association*; un 89% recibía tratamiento con inhibidores de la enzima de conversión de la angiotensina o antagonistas de los receptores de la angiotensina II; un 62%, con bloqueadores beta; un 86%, con diuréticos y un 74%, con antagonistas de los receptores de aldosterona. La media de la puntuación *Heart Failure Survival Score* fue de 8,75 ± 0,80. La puntuación mostró buena correlación con las variables derivadas de la prueba cardiorrespiratoria, como la captación de oxígeno máxima (0,662; $p < 0,01$), la captación de oxígeno en el umbral anaeróbico (0,644; $p < 0,01$), la pendiente de eficiencia ventilatoria de dióxido de carbono (–0,417; $p < 0,01$), el pulso de oxígeno (0,375; $p < 0,01$), la pendiente de eficiencia de captación de oxígeno (0,626; $p < 0,01$), la prueba de distancia recorrida en 6 min (0,370; $p < 0,01$), la fracción de eyección

Palabras clave:

Miocardiópatía

Insuficiencia cardiaca

Pronóstico

* Corresponding author: Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, United States.

E-mail address: renato.lopes@duke.edu (R.D. Lopes).

ventricular izquierda (0,650; $p = 0,01$) y el diámetro de la aurícula izquierda ($-0,377$; $p < 0,01$). Se observó también una correlación en el límite de la significación estadística entre la puntuación *Heart Failure Survival Score* y la calidad de vida ($-0,283$; $p < 0,05$).

Conclusiones: En pacientes con enfermedad de Chagas que presentaban insuficiencia cardiaca, la puntuación *Heart Failure Survival Score* mostró buena correlación con las principales variables de las pruebas funcionales pronósticas.

© 2011 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Abbreviations

6MWT: 6-minute walking test
 CPX: cardiopulmonary exercise test
 HF: heart failure
 HFSS: Heart Failure Survival Score
 MLHFQ: Minnesota Living with Heart Failure Questionnaire
 VE/VCO₂ slope: ventilatory carbon dioxide efficiency

INTRODUCTION

Heart failure (HF) is the end stage for almost all diseases that affect the heart. Despite progress in primary and secondary prevention of heart disease, HF is still a prevalent cause of mortality and hospitalization.¹

Several tools have been studied to assess HF prognosis. Scores and the cardiopulmonary exercise test (CPX) are the most established. The Heart Failure Survival Score (HFSS) is one of the most-studied and most-utilized scores in clinical practice.^{1–3} CPX is the best and most reproducible way to measure functional capacity and, by interpreting other variables obtained in the same test, the pathophysiology of patient symptoms can also be assessed. Based on the knowledge that HF is a multifactorial syndrome, the HFSS combines data from different prognostic markers in HF to better assess risk in this specific population.

Chagas disease is a prevalent cause of HF in Brazil and other Latin American countries.⁴ Imported cases are increasing in North America and Europe. The prognosis for HF that is due to Chagas disease seems to be worse than other etiologies.^{5,6} A specific score for prognostic assessment in Chagas disease has recently been published.⁷

Although CPX and its variables (peak oxygen uptake [VO₂], ventilatory carbon dioxide efficiency [VE/VCO₂ slope], heart rate recovery at the first minute, oxygen uptake efficiency slope [OUES], and oxygen pulse) and the 6-minute walking test (6MWT) have all been vastly studied in HF,^{8–13} HFSS performance in HF due to Chagas disease has not been evaluated. Thus, the aim of this study was to assess the correlation between the HFSS, a more generic HF score, and classic prognostic tests for HF in a population with symptomatic and advanced HF due to Chagas disease.

METHODS

Study Population

We studied 55 patients with HF due to Chagas disease. Patients had to be aged 18–75 years and have a Chagas serology confirmation by two distinct methods, as well as severe left ventricular dysfunction (ejection fraction <35%) and symptoms (New York Heart Association [NYHA] classes II–IV) after a period of stable drug therapy. The population comprised consecutive triage patients who fulfilled the above criteria and made all the specific

exams, as listed below, before their randomization into one of two distinct trial protocols that were being conducted on Chagas HF patients in our institution.¹⁴ From the total, 21 patients were selected for a trial that randomized patients to a treatment with autologous intracoronary stem cells or placebo; the remaining 34 patients were selected for a protocol that randomized patients to the use of pentoxifylline or granulocyte colony-stimulating factor or placebo. Both protocols were looking for improvements in left ventricular function. Patients with pulmonary diseases, primary heart valve disease, coronary obstruction lesions >50%, or those noncompliant with the drug treatment were not selected. Patients completed, as part of the entry exams for both protocols, the following exams: CPX, laboratory tests, electrocardiograms, 24-h Holter monitoring, 6MWT, clinical evaluation, and quality-of-life assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The study protocol was approved by an institutional review board, and all patients gave informed consent before entry.

Initial Evaluation

The initial evaluation of these patients included a clinical exam performed in all patients by the same physician. At this point, clinical and physical data were collected and NYHA class was determined using the HF-specific Goldman's specific activity scale. Blood samples for laboratory tests were collected after 12 h fasting. Electrocardiograms were performed with the patients in supine position after 5 min of rest. Two-dimensional color Doppler echocardiograms were performed on all patients by the same operator, ejection fractions were assessed using the Simpson method, and classic M-mode measures were determined. Then the Holter electrocardiogram monitoring was scheduled. The monitors were placed in the morning and removed the following morning. Patients were instructed to maintain their daily activities and medications during the recording period. The 6MWT was performed, by the same physician, using a finger pulse oximeter in a 30-meter-long hallway; the patient was instructed to walk in his or her most intense rhythm for 6 min, and the distance walked was determined for each patient. Also, the MLHFQ was completed by each patient.¹⁵

Cardiopulmonary Exercise Test Procedures

Symptom-limited CPX were performed on a treadmill with a breath-by-breath gas analyzer (Cortex MetaLyzer 3B; Cortex Biophysik, Leipzig, Germany) that was calibrated with gas before each test. An individualized ramp protocol was used to match a duration of 8 to 12 min for the exercise phase. Electrocardiograms were recorded at rest and in at least 2-min intervals during the exercise. Electrocardiogram monitoring was continued for at least 4 min of the recovery phase. Arterial pressure was verified at rest and at each minute throughout the entire exam. Ventilatory data collected breath-by-breath were tabulated in 10-s intervals. Peak VO₂ and exchange ratio were determined as the peak values achieved during the exercise phase. Anaerobic threshold was determined by the V-slope method.¹⁶ The VE/VCO₂ slope

was calculated based on the ventilation (VE) and CO₂ production (VCO₂) from the beginning of the exercise through the peak exercise, as in the linear regression model ($y=m\chi+b$, where m =slope). Based also upon previous publications, the cut point of >34 was used as a determinant of worse outcome for that variable.⁹ The same data from VE and VO₂ in that same interval were used to determine the OUES using previously published logarithmic equations.¹⁷ Heart rate recovery at the first minute was determined as the difference between: a) heart rate at peak exercise, and b) heart rate at the first minute of passive recovery. Based upon previous publications in HF populations, a cut point of <16 bpm was used as a risk marker.¹¹ Oxygen pulse was calculated as the ratio between peak VO₂ and peak heart rate and expressed as mL/beat.

Heart Failure Survival Score

The HFSS was calculated in accordance to its original publication using the variables inherent for each patient collected at the initial visit and basal exams.^{3,7}

HFSS=[(0.0216×rest heart rate)+(−0.0255×mean arterial pressure)+(−0.0464×ejection fraction)+(−0.047×serum sodium)+(−0.0546×peak VO₂)+(0.608×presence of interventricular conduction defect £)+(0.6931×presence of coronary arterial disease £)].

£ present=1 or absent=0

Statistical Analysis

Data were expressed as mean (standard deviation). Pearson correlation coefficients were used for association between variables. The patient population was divided into groups based on the peak VO₂ (peak VO₂ ≤12 mL/kg/min and peak VO₂ >12 mL/kg/min). Specific HF guidelines use this as a worse prognosis cut point for peak VO₂ in those treated with beta-blockers.² The HFSS values, CPX variable results, electrocardiogram variables, MLHFQ scores, and 6MWT results were compared between the 2 groups. The chi-square test was used for categorical variables, and the unpaired t-test was used for continuous variables. A *P* value <.05 determined significance.

RESULTS

Baseline Characteristics

Table 1 shows the demographic, clinical, and laboratory characteristics of the population. The majority of the patients were male (69%). Also, 89% of patients used angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists and 62% used beta-blockers. The mean value for the HFSS was 8.75 (0.80). Among the variables of this score, the mean values for sodium, mean arterial pressure, ejection fraction, and peak VO₂ were as follows: 138 mEq/L, 78 mmHg, 27.6%, and 17.3 mL/kg/min, respectively. Intraventricular conduction defect or paced rhythm was present in 47 patients (85%). No patients had coronary artery disease. The mean distance in the 6MWT was <400 m. The mean value for the MLHFQ was 38.

Echocardiography and Cardiopulmonary Test

Echocardiography data are shown in Table 2. The mean ejection fraction of 27.6% and mean left atrium diameter of 44 mm characterizes a group with severe cardiac dysfunction and volume overload.

CPX data are shown in Table 3. The mean exchange ratio was 1.08, which was compatible with a maximal exercise for the

Table 1
Baseline Characteristics and Medications

Total population, no.	55
Male sex, no. (%)	38 (69)
Age, years	52±9
NYHA class, no. (%)	
I	0 (0)
II	41 (74)
III	12 (22)
IV	2 (4)
Rhythm, no. (%)	
Sinus	40 (73)
Atrial fibrillation	6 (11)
Pacemaker	9 (16)
Clinical data	
Systolic pressure, mmHg	104±16
Mean arterial pressure, mmHg	78±13
Heart rate, bpm	68±8
BMI	24±3
Medication, % in use	
ACE inhibitors	60
ARBs	29
Beta-blockers	62
Diuretic	86
Digital	69
Aldosterone inhibitor	74
Laboratory data	
Hemoglobin, g/dL	14±1
Hematocrit, %	42±4
Sodium, mEq/L	138±4
Potassium, mEq/L	4.5±0.4
Urea, mg/dL	46±20
Creatinine, mg/dL	1.2±0.3
MLHFQ score	38±18
6-min walk distance, m	399±102
QRS duration, min	132±21
LBBB or RBBB or paced, %	85
Ventricular tachycardia detected on Holter, %	78
Low QRS voltage, %	11
HFSS, range	8.75±0.80 (7.05–10.69)
Chagas score, range	13±2 (8–20)

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; BMI, body mass index; HFSS, Heart Failure Survival Score; LBBB, left bundle branch block; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NYHA, New York Heart Association; RBBB, right bundle branch block. Data are expressed as mean±standard deviation or percentages, unless otherwise noted.

metabolic point of view (exchange ratio >1.05). The mean peak VO₂ was 17.3 mL/kg/min, compatible with a mean Weber et al.¹⁸ classification of II/IV. The mean VE/VCO₂ slope was 36 (>34). The mean percentage of the O₂ pulse was 74%. It is important to note that 61% of patients had an attenuated heart rate recovery of <16 bpm.

Heart Failure Survival Score and Heart Failure Prognostic Variables

Table 4 shows the correlations between HFSS and HF prognostic variables and the related beta and alpha regression coefficients.

Table 2
Echocardiogram Mean Values for the Total Population (n=55)

Variables	Mean values
Ejection fraction, %	27.6 (6.6)
LA diameter, mm	44 (7)
LV final systolic diameter, mm	60 (9)
LV final diastolic diameter, mm	68 (8.7)

LA, left atrium; LV, left ventricle.

Data are expressed as mean (standard deviation).

Table 3
General Cardiopulmonary Exercise Test Variable Characteristics (n=55)

Variables	Values
VO ₂ , mL/kg/min	17.3 (6.2)
Absolute VO ₂ , L/min	1.09 (0.47)
RER	1.08 (0.17)
VE/VCO ₂ slope	36 (10.6)
OUES, L/min	0.66 (0.27)
Peak O ₂ pulse, mL/beat	9.3 (3.5)
Peak O ₂ pulse achieved, %	74 (20)
VO ₂ at anaerobic threshold, mL/kg/min	11.6 (3.4)
HR recovery <16 bpm, %	61

HR, heart rate; OUES, oxygen uptake efficiency slope; VO₂, peak oxygen uptake; RER, exchange ratio; VE/VCO₂ slope, ventilatory carbon dioxide efficiency. Data are expressed as mean (standard deviation) or percentages.

The HFSS was associated with the CPX variables (peak VO₂, VO₂ in the anaerobic threshold, VE/VCO₂ slope (Figure), OUES, and O₂ pulse, 6MWT, ejection fraction, left atrium diameter, and MLHFQ score). Table 5 shows the comparison within groups for peak VO₂ >12 mL/kg/min or peak VO₂ ≤ 12 mL/kg/min. There was a significant difference in the HFSS, CPX variables, quality-of-life measurement, and 6MWT results between groups.

DISCUSSION

Our study focused on the analysis of the HFSS in patients with HF and Chagas disease. Importantly, we described the correlations between the HFSS and other prognostic variables of HF in a specific

population of Chagas HF and severe systolic dysfunction. Our cohort reflected a group of severe symptomatic Chagas disease HF patients with a mean ejection fraction of 27.6% and mean peak VO₂ of 17.3 mL/kg/min. We demonstrated that the HFSS was well associated with the main prognostic variables from the CPX, electrocardiogram, 6MWT, and questionnaire. By stratifying patients using a cut point of ≤12 mL/kg/min or >12 mL/kg/min for peak VO₂, we could demonstrate that those patients with the lower values in the group had a significantly lower HFSS.

The HFSS has been used since its publication to determine HF prognosis and has been validated in cohorts of patients independent of sex, race, and use of beta-blockers.^{19–21} It is also an accepted tool for heart transplant decision. Despite its vast use and divulgation, this score had not yet been tested in a Chagas HF population. Although there is already a specific score for HF due to Chagas disease, which includes all forms of Chagas cardiopathy (indeterminate, arrhythmic, and dilated forms), there is no specific score for Chagas patients with HF symptoms. Moreover, as the HFSS is already accepted for other etiologies, if it can also be used in HF due to Chagas it may facilitate the management of these patients in HF clinics, which usually treat patients with HF with different etiologies.

The population of our study represents a group of patients in the HF stages C and D according to American Heart Association guidelines.¹ Most patients were in NYHA classes II and III; this is in agreement with the mean peak VO₂ of 17.3 mL/kg/min, which is compatible with a mean class II/IV of Weber et al. classification.¹⁸ Previous studies stratified risk using the HFSS and classified groups as high, medium, and low risk using the respective cut points: <7.20, 7.20–8.09, and >8.09.³ The mean HFSS of our population was 8.75, which is compatible with a low-risk group. Using cut points for peak VO₂ (<10, 10–14, and >14 mL/kg/min) as determined by Mancini et al.,⁸ the group would also be set as a low-risk group, showing a similar risk stratification by VO₂ and HFSS analysis in this group of Chagas disease patients. On the other hand, Mady et al.²² found a survival rate of only 66% at 1 year in a Chagas HF population with a mean peak VO₂ of 18 mL/kg/min. This contrasts with the 94% survival rate found by Mancini et al.⁸ in general HF patients with a peak VO₂ >14 mL/kg/min.

Koelling et al.²¹ who analyzed a group of 500 ambulatory HF patients in the current era of HF treatment with a mean peak VO₂ of 15.7 mL/kg/min and mean ejection fraction of 21%, found a mean HFSS of 8.01. Compared with patients in Koelling et al. study, our patients had a higher prevalence of intraventricular conduction

Table 4
Correlations Between Prognostic Variables and Heart Failure Survival Score

Variable	HFSS (Pearson correlation)	Regression coefficients	
		α	β (95%CI)
VO ₂ , mL/kg/min	0.662 ^a	7.2	0.09 (0.06–0.11)
VO ₂ at anaerobic threshold, mL/kg/min	0.644 ^a	7.0	0.15 (0.10–0.20)
VE/VCO ₂ slope	–0.417 ^a	9.9	–0.03 (–0.05 to –0.01)
O ₂ pulse	0.375 ^a	7.9	0.08 (0.03–0.14)
OUES, L/min	0.626 ^a	7.5	1.8 (1.1–2.4)
6MWT, m	0.370 ^a	7.6	0.003 (0.001–0.005)
Ejection fraction, %	0.650 ^a	6.5	0.08 (0.05–0.1)
LA diameter, mm	–0.377 ^a	10.7	–0.04 (–0.07 to –0.10)
QOL	–0.283 ^b	9.2	–0.01 (–0.02 to –0)

6MWT, 6-min walking test; 95%CI, 95% confidence interval; HFSS, Heart Failure Survival Score; LA, left atrium; OUES, oxygen uptake efficiency slope; QOL, quality of life; VE/VCO₂ slope, ventilatory carbon dioxide efficiency; VO₂, peak oxygen uptake.^a P<.01.^b P<.05.

Table 5
Comparison Between Groups for Peak Oxygen Uptake

Variable	VO ₂ ≤ 12 mL/kg/min (n=9)	VO ₂ > 12 mL/kg/min (n=46)	P
VE/VCO ₂ slope	45.3 (13)	34.2 (9)	.003
RER	0.94 (0.16)	1.10 (0.16)	.011
O ₂ pulse, mL/beat	6.7 (2.6)	9.9 (3.4)	.012
VO ₂ at anaerobic threshold, mL/kg/min	7.4 (1.8)	12.5 (3)	.001
OUES	0.45 (0.23)	0.71 (0.26)	.008
Ejection fraction, %	25 (4.5)	28 (6.9)	.191
6MWT, min	279 (66)	415 (96)	.002
QOL	55 (13)	35 (17)	.002
HFSS	7.82 (0.45)	8.93 (0.73)	.001

6MWT, 6-minute walking test; HFSS, Heart Failure Survival Score; OUES, oxygen uptake efficiency slope; QOL, quality of life; RER, exchange ratio; VE/VCO₂ slope, ventilatory carbon dioxide efficiency; VO₂, peak oxygen uptake.

Data, except for P values, are expressed as mean (standard deviation).

defect (85% vs 25%). Of note, 56% of patients had ischemic cardiopathy in Koelling et al. study, which may be associated with a worse HFSS. Previous studies have shown that Chagas cardiopathy prognosis is worse than other etiologies, including ischemic.^{6,23} The mean heart rate in our patients was 68 bpm, which was lower than the mean of 81 bpm in Koelling et al. study, even though the percentage of beta-blocker use was similar (62% in our population vs 59% in Koelling et al. population). Because of specific characteristics inherent to the Chagas etiology that are related to prognosis and basal heart rate, for example, the cut points for the HFSS in this condition may differ from the general HF population.

We demonstrated that HFSS in Chagas HF patients is associated with the main functional capacity and ventilatory variables of the CPX, the 6MWT, ejection fraction, and quality of life. As the peak VO₂ is already part of the HFSS calculation, the association between these variables and with those dependent on the peak VO₂ was expected. The same is true for left ventricular ejection fraction. In recent years, many studies have shown the prognostic importance of the VE/VCO₂ slope in HF.^{9,11} This variable has an independent and even greater prognostic significance than peak VO₂. There is a linear correlation between VE and VCO₂ during exercise because the increment in dead space related to pulmonary congestion results in an elevation in VE, which in turn leads to a higher value for that ratio. The prognostic significance of this variable is maintained even in submaximal effort. We were able to show an association between the HFSS and the VE/VCO₂ slope (Figure). It is important to note that, for the HFSS calculation, we need data from variables acquired from different exams; for the VE/VCO₂ slope calculation, all data are derived from a unique CPX. For the development of any score in a certain disease, it is necessary to have a good understanding of the variables and their association with outcomes. All variables are not always readily available in a first appointment to calculate a given score. Therefore, understanding individual variables as well as their correlations with well-validated scores is important and might help decision making, particularly when variables used to calculate the scores are still unavailable to be used in the initial visits.

Mortality is not the only important outcome in HF. Quality of life also assumes an important and relevant role. Some therapies extend life without increasing quality of life. Researchers have studied how quality of life relates to functional variables^{24–26} and have come to different conclusions. How HFSS relates to quality of life had not yet been studied. In our population, we were able to show a weak but statistically significant correlation between quality of life (as assessed by the MLHFQ) and the HFSS.

Guidelines accept a peak VO₂ of ≤ 12 mL/kg/min as a criterion for heart transplant selection in symptomatic patients with HF using optimized evidence-based medication, including beta-blockers.² In our study, we split the population into 2 groups of better and worse prognosis based on the peak VO₂, and it showed that functional variables and quality of life differed within groups in the same way that HFSS differed in statistical significance between groups. The mean HFSS in the group with peak VO₂ ≤ 12 mL/kg/min was 7.82, compatible with a medium-risk HFSS. The mean 6MWT distance and the VE/VCO₂ slope value in the ≤ 12 mL/kg/min group (279 m and 45.3, respectively) were compatible with high risk (< 300 m)¹³ and with a respiratory class of IV as assessed by the VE/VCO₂ slope (VE/VCO₂ slope > 44).¹¹

Limitations

Our study has some limitations. First, the sample size is small. Second, this is a single-center study. Third, we did not collect data on right ventricular function, which has been demonstrated to be of value for predicting functional capacity in Chagas patients;²⁷ thus, we could not test the correlations between HFSS and right ventricular function in this population. Finally, we do not have clinical outcomes that test the correlation between the cardiopulmonary and echocardiographic variables with clinical outcomes.




Figure. Scatter plot graphic representation of the correlations between Heart Failure Survival Score and ventilatory carbon dioxide efficiency, VE/VCO₂ slope.

CONCLUSIONS

In HF patients with Chagas disease, the HFSS correlated well with the main prognostic functional test variables but had a weak correlation with quality of life. As expected, patients with lower functional classes had a lower HFSS. The HFSS might be a useful tool for prognostic assessment in HF due to Chagas disease. Studies with longitudinal and clinical follow-up are required to better determine the optimal thresholds of the HFSS for decision making in this specific population.

FUNDING

This study was fully funded by the Brazilian Ministry of Health, Foundation for Research Support of the State of Bahia, and the Brazilian Clinical Research Institute in São Paulo, Brazil.

CONFLICTS OF INTEREST

None declared.

REFERENCES

- Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009;119:1977–2016.
- Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006. *J Heart Lung Transplant*. 2006;25:1024–42.
- Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. *Circulation*. 1997;95:2660–7.
- Hernández-Leiva E. Epidemiología del síndrome coronario agudo y la insuficiencia cardíaca en Latinoamérica. *Rev Esp Cardiol*. 2011;64:34–43.
- Pereira Nunes MC, Barbosa MM, Ribeiro AL, Amorim Fenelon LM, Rocha MO. Factores predictivos de la mortalidad en pacientes con miocardiopatía dilatada: importancia de la enfermedad de Chagas como etiología. *Rev Esp Cardiol*. 2010;63:788–97.
- Bestetti RB, Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. *Int J Cardiol*. 1997;60:187–93.
- Rassi Jr A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. *N Engl J Med*. 2006;355:799–808.
- Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds Jr LH, Wilson JR, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. *Circulation*. 1991;83:778–86.
- Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Peak VO_2 and VE/VCO_2 slope in patients with heart failure: a prognostic comparison. *Am Heart J*. 2004;147:354–60.
- Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. Development of a ventilatory classification system in patients with heart failure. *Circulation*. 2007;115:2410–7.
- Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. The prognostic value of heart rate response during exercise and recovery in patients with heart failure: influence of beta-blockade. *Int J Cardiol*. 2010;138:166–73.
- Oliveira RB, Myers JN, Araujo CGS, Arena R, Mandic S, Bensimhon D, et al. Does peak oxygen pulse complement peak VO_2 in risk stratifying patients with heart failure? *Am J Cardiol*. 2009;104:554–8.
- Guazzi M, Dickstein K, Vicenzi M, Arena R. Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. *Circ Heart Fail*. 2009;2:549–55.
- Cell Therapy in Chagas Cardiomyopathy. ClinicalTrials.gov Web site [updated 2010 Jan 24; accessed 2011 Dec 16]. Available from: <http://clinicaltrials.gov/ct2/show/NCT00349271?term=NCT00349271&rank=1>
- Carvalho VO, Guimarães GV, Carrara D, Bacal F, Bocchi EA. Validation of the Portuguese version of the Minnesota Living with Heart Failure Questionnaire. *Arq Bras Cardiol*. 2009;93:39–44.
- Pedrosa RC, Melo MF, Saad EA. Anaerobic threshold detected using “V-slope analysis” in chronic chagasic disease. *Rev Soc Bras Med Trop*. 1997;30:129–38.
- Baba R, Nagashima M, Goto M, Nagano Y, Yokota M, Tauchi N, et al. Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise. *J Am Coll Cardiol*. 1996;28:1567–72.
- Weber KT, Kinasevitz GT, Janicki JS, Fishman AP. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. *Circulation*. 1982;65:1213–23.
- Green P, Lund LH, Mancini D. Comparison of peak exercise oxygen consumption and the Heart Failure Survival Score for predicting prognosis in women versus men. *Am J Cardiol*. 2007;99:399–403.
- Goda A, Lund LH, Mancini DM. Comparison across races of peak oxygen consumption and heart failure survival score for selection for cardiac transplantation. *Am J Cardiol*. 2010;105:1439–44.
- Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. *J Heart Lung Transplant*. 2004;23:1414–22.
- Mady C, Cardoso RH, Barretto AC, Da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. *Circulation*. 1994;90:3098–102.
- Areosa CM, Almeida DR, Carvalho AC, Paola AA. Evaluation of heart failure prognostic factors in patients referred for heart transplantation. *Arq Bras Cardiol*. 2007;88:667–73.
- Nogueira ID, Servantes DM, Nogueira PA, Pelcerman A, Salvetti XM, Salles F, et al. Correlation between quality of life and functional capacity in cardiac failure. *Arq Bras Cardiol*. 2010;95:238–43.
- Athanasopoulos LV, Dritsas A, Doll HA, Cokkinos DV. Comparative value of NYHA functional class and quality-of-life questionnaire scores in assessing heart failure. *J Cardiopulm Rehabil Prev*. 2010;30:101–5.
- Carson P, Tam SW, Ghali JK, Archambault WT, Taylor A, Cohn JN, et al. Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. *J Card Fail*. 2009;15:835–42.
- Nunes Mdo C, Beloti FR, Lima MM, Barbosa MM, Pinto Filho MM, De Barros MV, et al. Functional capacity and right ventricular function in patients with Chagas heart disease. *Eur J Echocardiogr*. 2010;11:590–5.